Use ← → keys or buttons to navigate

Alcohol Withdrawal Management Protocol

Evidence-Based Symptom-Triggered Therapy for ED and Inpatient Settings

Target Audience
ED & Inpatient Physicians, APPs, Nursing
Duration
45 Minutes
CE Credits
1.0 CME
Slide 02

Learning Objectives

Assess alcohol withdrawal severity using CIWA-Ar scoring and identify patients at risk for complications
Select appropriate benzodiazepine therapy based on patient comorbidities and hepatic function
Implement symptom-triggered protocols for effective withdrawal management
Recognize escalation criteria requiring ICU transfer and phenobarbital therapy
Apply edge case protocols for special populations (pregnancy, elderly, concurrent use disorders)
Slide 03

The Clinical Problem

📊
Epidemiology & Impact
5% of US adults will experience alcohol withdrawal in their lifetime
3-5% of patients withdrawing develop delirium tremens (DTs)
1-4% mortality for untreated DTs; ~15% mortality for untreated seizures
Properly treated withdrawal has < 1% mortality

Fixed-schedule vs. Symptom-Triggered: Fixed-schedule protocols result in 2-3x more benzodiazepine administration without improved outcomes. Symptom-triggered therapy (CIWA-Ar ≥10) delivers:

  • 50% reduction in total benzodiazepine dose
  • Shorter duration of treatment (2.8 vs 5.4 days)
  • Reduced oversedation and respiratory complications
  • Same seizure/DT prevention efficacy

Reference: Saitz et al., JAMA 1994; Daeppen et al., Ann Intern Med 2002

Slide 04

CIWA-Ar Assessment Tool

Domain Assessment Points Max Score
Nausea/Vomiting 0=None, 7=Constant nausea, frequent dry heaves 7
Tremor 0=None, 7=Severe, even with arms extended 7
Paroxysmal Sweats 0=None, 7=Drenching sweats 7
Anxiety 0=None, 7=Acute panic states 7
Agitation 0=Normal, 7=Pacing or thrashing 7
Tactile Disturbances 0=None, 7=Continuous hallucinations 7
Auditory Disturbances 0=None, 7=Continuous hallucinations 7
Visual Disturbances 0=None, 7=Continuous hallucinations 7
Headache 0=None, 7=Extremely severe 7
Orientation/Clouding 0=Oriented, 4=Disoriented 4
<10
Mild
Reassess; may not require treatment
10-19
Moderate
Start symptom-triggered protocol
≥20
Severe
Aggressive treatment; consider ICU
Slide 05

Risk Stratification Framework

Low
Risk Factors
  • ✓ CIWA < 15
  • ✓ No prior seizures/DTs
  • ✓ Adequate social support
  • ✓ No medical comorbidities
Mod
Risk Factors
  • ✓ CIWA 15-24
  • ✓ Age 60-65
  • ✓ Prior withdrawal episodes
  • ✓ Moderate medical issues
High
Risk Factors
  • ✓ CIWA > 25
  • ✓ Age > 65
  • ✓ Prior seizures or DTs
  • ✓ Significant comorbidities

Strongest predictors of DTs/seizures:

  • History of prior withdrawal seizure (RR 5.2)
  • History of prior DTs (RR 7.8)
  • Blood alcohol level > 200 mg/dL at presentation
  • Duration of heavy drinking > 10 years
  • Time since last drink > 48 hours

Note: These factors inform monitoring intensity, not necessarily treatment threshold (still CIWA ≥10)

Slide 06

Clinical Workflow Algorithm

1
Triage
Suspected AUD,
obtain CIWA-Ar
→
2
Risk Stratify
Score ≥10?
Medical hx review
→
3
Treat
Benzo protocol,
thiamine first
→
4
Monitor
CIWA q1-2h,
vitals q4h
→
5
Escalate/DC
Refractory?
CIWA <10 x24h
⚠️ CRITICAL SAFETY STEP

Thiamine MUST precede glucose administration. Glucose metabolism in thiamine-deficient patients can precipitate Wernicke encephalopathy. Give thiamine 100-500mg IV before any dextrose-containing fluids.

Slide 07

Benzodiazepine Selection Guide

Agent Initial Dose Route Half-life Best For Avoid If
Lorazepam 2-4mg q1h PRN PO/IV 10-20h Hepatic impairment, elderly —
Chlordiazepoxide 25-100mg q6h PO 24-48h Younger, intact liver Cirrhosis, severe hepatic disease
Diazepam 10-20mg q1-2h PO/IV 20-80h Rapid control needed Elderly, hepatic impairment
Phenobarbital 130-260mg IV IV 80-120h Refractory withdrawal, ICU Outpatient, mild withdrawal

Why benzodiazepines work: Alcohol enhances GABA-A receptor function. Chronic use causes receptor downregulation. Abrupt cessation → GABA deficiency → neuronal hyperexcitability → withdrawal syndrome. Benzodiazepines are GABA-A agonists that "substitute" for alcohol.

Lorazepam vs. Chlordiazepoxide: Lorazepam undergoes glucuronidation (safer in liver disease). Chlordiazepoxide relies on hepatic oxidation (longer-acting but accumulates in cirrhosis).

Phenobarbital advantage: Different receptor site (GABA-A allosteric modulator), reduces need for mechanical ventilation vs. high-dose benzodiazepines in severe cases.

Slide 08

Case Study: Maria

👤
42-year-old female, Day 2 of withdrawal

History: 15 years heavy alcohol use (1 bottle wine + 4-5 shots daily). Last drink 36 hours ago. Two prior withdrawal episodes, no seizures.

BP
168/94
HR
118
Temp
99.8°F
CIWA-Ar
22

Additional findings: Tremulous, diaphoretic, anxious but oriented. Mildly elevated AST/ALT (2x ULN). Albumin 3.2.

Assessment: Moderate-severe withdrawal (CIWA-Ar 22). Compensated liver disease suggested by low albumin + elevated LFTs.

Management decisions:

  • Agent: Lorazepam (safer in hepatic impairment)
  • Dosing: Start 2mg IV q1h PRN per protocol
  • Monitoring: CIWA q1h, vitals q2h, seizure precautions
  • Supportive: Thiamine 100mg IV daily x3d, folate, MVI
  • Setting: Monitored bed (not ICU, no seizure history but close observation)

Why not chlordiazepoxide? Long half-life and hepatic metabolism risk accumulation in compensated cirrhosis → encephalopathy.

Slide 09

Refractory Withdrawal & ICU Escalation

⚠️ ESCALATION CRITERIA
  • CIWA-Ar > 25 despite 3+ doses of benzodiazepines
  • Hemodynamic instability (SBP <90 or >200, HR >140)
  • Active seizures or status epilepticus
  • Delirium tremens (confusion + autonomic instability + hallucinations)
  • Respiratory depression from benzodiazepine therapy
  • Need for mechanical ventilation

Phenobarbital Protocol

Initial Dose 130-260mg IV
Repeat q15-30min PRN
Max Loading 10-15 mg/kg
Monitoring Continuous EEG, ICU

Adjunctive Options

Dexmedetomidine 0.2-0.7 mcg/kg/hr
Propofol 5-50 mcg/kg/min
Ketamine 0.3-0.5 mg/kg bolus
Indication Sedation adjunct
Slide 10

Delirium Tremens: Recognition & Management

Diagnostic Triad: (1) Altered mental status/confusion, (2) Autonomic instability (tachycardia, hypertension, fever), (3) Visual/tactile hallucinations
Onset: Typically 48-96 hours after last drink; can occur up to 10 days
Mortality: 1-4% with treatment; 15-20% without treatment
1
ICU Admit
Continuous monitoring
2
IV Lorazepam
Aggressive titration
3
Add Phenobarbital
If refractory
4
Dexmedetomidine
Agitation adjunct
5
Supportive Care
Fluids, electrolytes

Avoid: Antipsychotics as monotherapy (lower seizure threshold). If absolutely needed for hallucinations, use with concurrent benzodiazepine.

Slide 11

Edge Cases & Special Populations

🤰 Pregnancy

Preferred Agent Lorazepam
Key Principle Treat withdrawal
Risk Note Untreated > treated
Monitoring Fetal heart tones

👴 Elderly (>65)

Dosing Start at 50%
Agent Choice Lorazepam preferred
Monitoring Fall precautions
Risk Delirium, falls

💊 Benzo Use Disorder

Approach Phenobarbital-first
Setting ICU preferred
Dose May need higher
Duration Longer expected

⚠️ Concomitant SSRI

Contraindication Tramadol
Risk Serotonin syndrome
Alternative Acetaminophen
Monitor Agitation, clonus
Slide 12

Monitoring & Safety Protocol

Parameter Frequency Target/Action Red Flags
CIWA-Ar q1-2h (q1h if ≥15) Treat if ≥10; goal <10 >25, increasing trend
Vitals q4h (q2h if CIWA≥20) Stable hemodynamics SBP <90, HR >140
Electrolytes Daily (BMP) Replete Mg, K, Phos Mg <1.2, K <3.0
Glucose q6h initially 80-180 mg/dL Hypoglycemia
Oxygen Continuous pulse ox SpO2 >92% Respiratory depression
Fluid Balance I&O monitoring +500 to +1000 mL/day Volume overload
  • Magnesium: If < 1.5 mg/dL, give 2g IV over 15 min; if 1.5-1.8, give 1g. Repeat daily (repletion continues with oral replacement)
  • Potassium: If < 3.5 mEq/L, replace IV with cardiac monitoring. Target 4.0-4.5 for seizure prophylaxis
  • Phosphorus: If < 2.0 mg/dL, give 15-30 mmol IV over 4-6h (watch for hypocalcemia)
  • Thiamine: 100-500mg IV daily x3d, then 100mg PO daily (give BEFORE glucose)
Slide 13

Implementation Checklist

Obtain CIWA-Ar score at triage
Order labs (CMP, LFTs, Mg, Phos, BAL)
Medication reconciliation (check tramadol/SSRIs)
Thiamine 100-500mg IV BEFORE any glucose
Order seizure precautions (padded rails, suction)
Initiate symptom-triggered benzo protocol
CIWA-Ar reassessment q1-2h scheduled
Addiction psychiatry consult placed
Nutritional support (MVI, folate, thiamine)
Discharge follow-up arranged (naltrexone?)

Inter-rater reliability is critical. Studies show 20-30% variation in CIWA scoring between untrained nurses.

  • Annual competency validation required
  • Video-based training with standardized patients
  • Co-signing requirement for CIWA >20 (dual nurse assessment)
  • Consider electronic CIWA calculator in EHR to standardize
Slide 14

Discharge Criteria & Planning

Discharge Criteria: CIWA-Ar < 10 for 24 consecutive hours, stable vitals, tolerating PO, able to ambulate safely
Do NOT discharge with benzodiazepine prescription (unless specific taper protocol ordered by addiction psych)
Bridge to treatment: Addiction psych referral, PHP/IOP placement, telehealth appointments scheduled

✓ Discharge Ready

CIWA-Ar <10 x24h
Vitals Stable >4h
Mental Status Oriented, coherent
Follow-up Scheduled within 72h

✗ DO NOT Discharge

CIWA-Ar ≥10 within 24h
Social Homeless, no support
Medical Unstable comorbidity
Psych Active SI, severe CI
Slide 15

Post-Withdrawal: AUD Pharmacotherapy

Agent Mechanism Dosing Timing After Withdrawal Contraindications
Naltrexone Mu-opioid antagonist 50mg PO daily Once CIWA <10 x24h Opioid use ( precipitates withdrawal)
Acamprosate Glutamate modulation 666mg PO TID Can start during withdrawal Severe renal impairment
Disulfiram ALDH inhibitor 250mg PO daily ≥72h after last drink Severe cardiac disease, pregnancy
Topiramate GABA/glutamate 25-75mg BID Titrate as tolerated History of kidney stones

Naltrexone: First-line for most patients. Reduces heavy drinking days by ~25%. Requires opioid-free status. Depot formulation available (380mg IM q4wk).

Acamprosate: Best for maintaining abstinence (not reducing drinking). Can start during withdrawal. TID dosing affects adherence.

Disulfiram: Only for highly motivated patients with observed dosing. "Sick not drunk" approach requires informed consent.

Topiramate: Off-label but effective. Useful for patients with comorbid migraine or obesity. Slow titration reduces side effects.

Slide 16

Key Takeaways

Assessment

  • CIWA-Ar ≥10 triggers treatment
  • Risk stratify by history & score
  • Thiamine before glucose always

Treatment

  • Symptom-triggered benzodiazepines
  • Lorazepam for hepatic impairment
  • Monitor q1-2h with CIWA

Escalation

  • ICU for CIWA >25 or DTs
  • Phenobarbital for refractory cases
  • Consider dexmedetomidine adjunct

Discharge

  • CIWA <10 x24h required
  • Bridge to addiction treatment
  • Consider naltrexone initiation
Remember: Untreated withdrawal carries 15-20% mortality for DTs. Properly treated: <1%. Early recognition and protocolized care saves lives.
Slide 17

References & Further Reading

Saitz R, et al. Individualized treatment for alcohol withdrawal: A randomized double-blind controlled trial. JAMA. 1994;272(7):519-523.
Daeppen JB, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal. Ann Intern Med. 2002;136(10):783-782.
ASAM Clinical Practice Guideline. Alcohol Withdrawal Management. 2024. American Society of Addiction Medicine.
Mayo-Smith MF. Pharmacological management of alcohol withdrawal: A meta-analysis and evidence-based practice guideline. JAMA. 1997;278(2):144-151.
Stahl SM. Stahl's Essential Psychopharmacology. 5th Edition. Cambridge University Press; 2021. Chapter 13: Substance Use Disorders.

Thank You

Questions & Discussion

Questions?
See Speaker Companion for Q&A
Resources
Clinical Guide & Enrichment Materials
1 / 18